Interpace Biosciences, INC 8-K filings

Interpace Biosciences announced Q2 2026 results, with thyroid revenue up 9% year-over-year to $9.1 million, alongside improved income from continuing operations and Adjusted EBITDA.

Interpace Biosciences announced first quarter 2026 financial results, reporting $9.0 million in revenue and $0.8 million in income from continuing operations, with a 12% year-over-year increase in thyroid revenue.

Interpace Biosciences announced its fourth quarter and full year 2025 financial results, highlighting strong thyroid segment growth and a significant non-cash tax benefit.

Interpace Biosciences announced preliminary 2025 thyroid testing revenue growth of 21%, initiated 2026 guidance, converted all preferred stock, and plans a Nasdaq uplisting.

Interpace Biosciences announced the early repayment of its term loan facility with BroadOak Capital Partners, enhancing financial flexibility and supporting future growth.

Interpace Biosciences announced its third quarter 2025 financial results, highlighting record thyroid test volumes and revenue, alongside improved cash collections and operational efficiencies.

Interpace Biosciences reports a 23% revenue decrease in Q2 2025 due to PancraGEN wind-down, but sees record thyroid test volume and revenue growth.

Interpace Biosciences announces a 13% year-over-year revenue increase in Q1 2025, driven by record thyroid test volume and revenue, and initiates full-year revenue guidance of approximately $38 million.

Interpace Biosciences implements a restructuring plan to mitigate the financial impact of Medicare's decision to end reimbursement for its PancraGEN test.

Interpace Biosciences will restate financial statements from 2023 and 2024 due to an error in the accrual of royalty expenses, which overstated liabilities and will positively impact stockholders' equity and net income.

Interpace Biosciences announces a delay in the implementation of a Medicare coverage determination that would have impacted its PancraGEN test, leading the company to re-evaluate its restructuring plan.

Interpace Biosciences has amended its loan agreement with BroadOak Fund V, L.P., and initiated a restructuring plan including workforce reductions to offset revenue losses.

Interpace Biosciences will discontinue its PancraGEN test after February 7, 2025, due to a final Local Coverage Determination by the Centers for Medicare & Medicaid Services that establishes non-coverage for the test.

Interpace Biosciences' stockholders ratified the appointment of EisnerAmper, LLP as the company's independent auditor for the fiscal year ending December 31, 2024, at their annual meeting on November 12, 2024.

Interpace Biosciences reports record third-quarter revenue of $12.3 million, a 35% increase year-over-year, driven by strong test volume growth and improved profitability.

Interpace Biosciences has exchanged its Series B preferred stock for a new Series C preferred stock, a move aimed at facilitating a potential uplisting to the Nasdaq stock exchange.

Interpace Biosciences reported record revenue, test volume, and cash collections for Q2 2024, driven by increased adoption of its molecular diagnostic tests and improved operational efficiency.

Interpace Biosciences announced a 4% year-over-year revenue increase to $10.3 million and a 10% increase in test volume for the first quarter of 2024.

Interpace Biosciences announced record revenue, income, and cash collections for the fourth quarter and full year 2023, marking a significant turnaround in financial performance.